ALSPW Spineway SAS

Spineway : First-quarter 2025 revenue of €2.8 million

Spineway : First-quarter 2025 revenue of €2.8 million

Press release        

Ecully, April 16, 2025 – 7.00 p.m.



SPINEWAY

First-quarter 2025 revenue of €2.8 million

In thousands of euros20252024Change



as a %
Q1 revenue2,8283,070-8%

Unaudited consolidated data

Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.8 million in the first quarter of 2025, stable compared with the fourth quarter of 2024 and down 8% on the revenue for the first quarter of 2024, which constitutes a high comparison base.

The development of export sales (outside Europe) continued in the first quarter of 2025, with revenue up 9% year on year at €1.4 million, representing 50% of total revenue for the quarter. The Asia and Middle East-Africa regions were the drivers of this growth.

In the other regions, first-quarter revenue was stable in France (-3%) but was hit harder in Europe (-37%), penalized by the high 2024 baseline. The Group is currently working to optimize its market access strategy in the main European countries and to strengthen its distribution network in this region.

Spineway confirms its full-year growth target for 2025 and the rollout of its multi-year program of approvals in its key markets, in line with its strategic aim of becoming a major player in less invasive spine treatments.

Next events:

June 4, 2025 – General Meeting

July 30, 2025 – H1 2025 revenue

SPINEWAY IS ELIGIBLE FOR PEA-SME (EQUITY SAVINGS PLANS FOR SMES)

Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.

Spineway has an international network of over 50 independent distributors and more than 70% of its revenue comes from exports.

ISIN: FR001400N2P2 – ALSPW 

Contacts:





SPINEWAY



Shareholder-services line



Available Tuesday through Thursday



+33 (0)806 706 060		 



AELIUM



Investor relations



Solène Kennis



Attachment



EN
16/04/2025

Underlying

ALSPWSpineway SAS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spineway SAS

 PRESS RELEASE
Free
ALSPW SPINEWAY SAS

Spineway : First-quarter 2025 revenue of €2.8 million

Spineway : First-quarter 2025 revenue of €2.8 million Press release         Ecully, April 16, 2025 – 7.00 p.m. SPINEWAY First-quarter 2025 revenue of €2.8 million In thousands of euros20252024Change as a %Q1 revenue2,8283,070-8% Unaudited consolidated data Spineway, a specialist in innovative implants for the treatment of severe spine disorders, recorded revenue of €2.8 million in the first quarter of 2025, stable compared with the fourth quarter of 2024 and down 8% on the revenue for the first quarter of 2024, which constitutes a high comparison base. The development of export sales...

April 16, 2025 1 EN
 PRESS RELEASE
Free
ALSPW SPINEWAY SAS

SPINEWAY : Chiffre d’affaires du 1er trimestre 2025 de 2,8 M€

SPINEWAY : Chiffre d’affaires du 1er trimestre 2025 de 2,8 M€ Communiqué de presse          Ecully, le 16 avril 2025 – 19h SPINEWAY Chiffre d’affaires du 1er trimestre 2025 de 2,8 M€ En milliers d’euros20252024Variation en %CA 1er trimestre2 8283 070- 8% Données consolidées non auditées Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), a réalisé sur le 1er trimestre 2025 un chiffre d’affaires de 2,8 M€, stable par rapport au 4ème trimestre 2024 et en recul de 8% par rapport au chiffre d’affaires du 1er trimestre...

April 16, 2025 1 EN
 PRESS RELEASE
Free
ALSPW SPINEWAY SAS

Spineway : Consolidated 2024 annual results - Operating income close t...

Spineway : Consolidated 2024 annual results - Operating income close to breakeven Press release         Ecully, March 24, 2025 – 6 p.m. SPINEWAY Consolidated 2024 annual results Annual revenue of €12 million (+14%)Operating income close to breakevenReduction in net loss In thousands of eurosConsolidated accounts20242023Revenue11,95010,519Cost of sales(3,699)(3,309)Gross margin% of revenue8,25069%7,21069%Net operating expensesOf which running costs(9,131)(3,900)(11,727) (5,424)Of which personnel expenses(4,890)(5,659)Operating income/(loss)(881)(4,517)Financial income/(expense)Includin...

March 24, 2025 1 EN
 PRESS RELEASE
Free
ALSPW SPINEWAY SAS

SPINEWAY : Résultats annuels 2024 consolidés - Résultat d’exploitation...

SPINEWAY : Résultats annuels 2024 consolidés - Résultat d’exploitation proche de l’équilibre Communiqué de presse          Ecully, le 24 mars 2025 –18h SPINEWAY Résultats annuels 2024 consolidés Chiffre d’affaires annuel de 12 M€ (+ 14%)Résultat d’exploitation proche de l’équilibreRéduction de la perte nette En milliers d'eurosComptes consolidés20242023Chiffre d'affaires11 95010 519Coût des ventes-3 699- 3 309Marge brute% du CA8 25069%7 21069%Coûts nets d’exploitationDont coûts de fonctionnement- 9 131-3 900- 11 727 - 5 424Dont charges de personnel- 4 890- 5 659Résultat d’exploitati...

March 24, 2025 1 EN
 PRESS RELEASE
Free
ALSPW SPINEWAY SAS

SPINEWAY : Point sur la procédure judiciaire contre Strategos

SPINEWAY : Point sur la procédure judiciaire contre Strategos Communiqué de presse          Ecully, le 21 mars 2025 – 8h45 SPINEWAY Point sur la procédure judiciaire contre Strategos Spineway, spécialiste des implants innovants pour le traitement des pathologies sévères de la colonne vertébrale (rachis), annonce que la Cour d’appel du Deleware (United States Court of Appeals for the third circuit) a décidé, dans un jugement rendu le 19 mars 2025, de confirmer la décision rendue en première instance et déboutant le groupe Spineway de sa demande d’exécution de la sentence arbitrale rend...

March 21, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch